DFTX - Mind Medicine (MindMed) Inc.

17.5
-0.380   -2.171%

Share volume: 1,613,092
Last Updated: 03-30-2026
Pharmaceutical Products/Medicinal Chemicals: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$17.88
-0.38
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
56%
Profitability 50%
Dept financing 37%
Liquidity 45%
Performance 70%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.60%
1 Month
-1.07%
3 Months
30.69%
6 Months
41.93%
1 Year
199.15%
2 Year
83.82%
Key data
Stock price
$17.50
P/E Ratio 
0.00
DAY RANGE
$17.13 - $17.70
EPS 
-$2.06
52 WEEK RANGE
$4.70 - $19.67
52 WEEK CHANGE
$215.88
MARKET CAP 
1.319 B
YIELD 
N/A
SHARES OUTSTANDING 
99.698 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
1.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,623,545
AVERAGE 30 VOLUME 
$1,766,504
Company detail
CEO: Robert Barrow
Region: US
Website: mindmed.co
Employees: 40
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Medicinal Chemicals
Sector: Manufacturing

Mind Medicine (MindMed) Inc. develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder.

Recent news